New targeted therapy combo shows promise for HER2+ breast cancer
NCT ID NCT05319873
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of targeted drugs (ribociclib, tucatinib, trastuzumab, with or without fulvestrant) for HER2-positive breast cancer. In the first part, it looks at safety in patients whose cancer has spread. In the second part, it compares these drugs to standard chemotherapy before surgery in early-stage patients. The goal is to see if the new combo can shrink tumors more effectively and reduce the amount of tissue that needs to be removed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE II BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Engineered immune cells join chemo and antibody to attack Hard-to-Treat breast cancer
- Can a vaccine train the immune system to hunt down hidden breast cancer cells?
- Could a common cholesterol drug boost breast cancer treatment?
- Strawberry compound could help breast cancer survivors walk farther
- Strawberry compound and exercise may keep breast cancer survivors from becoming frail